Knight Therapeutics Inc. (TSX:GUD)

Market Cap	586.80M
Revenue (ttm)	413.85M
Net Income (ttm)	-3.49M
Shares Out	99.29M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	189.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,863
Average Volume	52,407
Open	6.05
Previous Close	6.05
Day's Range	5.91 - 6.05
52-Week Range	5.25 - 6.55
Beta	0.11
RSI	41.01
Earnings Date	Mar 19, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD